Journal of International Psychiatry

【Abstract】Objective To investigate the therapeutic effect of paroxetine hydrochloride in patients with chronic atrophic gastritis (CAG) with anxiety and depression, and to analyze its effect on gastrointestinal hormone levels and neurotransmitter levels. Methods From September 2018 to October 2020, 107 patients with CAG with anxiety and depression in our hospital were enrolled as observation objects. They were divided into 2 groups by tossing the coin. 53 patients in the control group received omeprazole enteric-coated capsules. 54 cases in the observation group were treated with paroxetine hydrochloride, and the anxiety and depression scores and gastrointestinal hormone levels were compared between the two groups. Results Before treatment, there was no significant difference in gastrointestinal hormone levels, anxiety and depression scores and neurotransmitter levels between the two groups of patients (P>0.05); after treatment, the MTL and GAS levels of the observation group were significantly lower than those of the control group (P<0.05) The scores of HAD-A, HAD-D, HAMA and HAMD of the observation group were lower than those of the control group, and 5-HT and dopamine levels were higher than those of the control group (P<0.05). Conclusion Paroxetine hydrochloride can significantly regulate gastrointestinal hormone levels and neurotransmitter levels in CAG patients with anxiety and depression, improve the negative emotions of CAG patients, and restore gastrointestinal function. It is worth recommending.

[Keywords] Paroxetine hydrochloride; chronic atrophic gastritis; gastrointestinal hormones; anxiety and depression